This innovative technology is designed to address the two critical limitations of current T cell therapies: refractory relapse due to tumor heterogeneity and toxicity caused by effector cell over-activation. Dr. Gambles, co-inventor and co-founder of the University of Utah spin-out, Thera-T Pharmaceutics, details how MATCH advances the field of multispecific antibodies for liquid tumors like leukemia, lymphoma, and multiple myeloma.

Rethinking Bispecifics: The MATCH Advantage Unlike a traditional bispecific antibody with a fixed 1:1 ratio , the MATCH platform splits the antibody into two distinct components: the T cell engaging fragment and the cancer cell engaging fragment. These fragments are functionalized with complimentary, stabilized oligonucleotides (oligos) that enable them to spontaneously and rapidly self-assemble in solution. This split-molecule architecture provides two revolutionary advantages: Modular Multi-Specificity: The platform is highly modular. Researchers can exchange different cancer cell binders and create multi-specific cocktails that target upwards of two, three, or four antigens simultaneously. This customized approach directly combats the problem of heterogeneous cancer populations and helps prevent refractory relapse. Tunable Dosing & Reduced Toxicity: By separating the binding events , the dose of the cancer cell engager can be optimized separately from the effector cell engager. This allows for a two-step dosing regimen: pre-coating the cancer cells with a high engager dose, followed by a significantly lower T cell engager dose to recruit T cells. This fine-tuned control over T cell activation significantly reduces cytokine release and toxicity compared to clinical standard bispecific antibodies.

Key Findings & Validation Dr. Gambles presents compelling data validating the platform's efficacy and tunability: In Vitro Multi-Antigen Killing: The same cohort of T cells was successfully used to kill three different cancers sequentially—lymphoma (CD20-targeting), multiple myeloma (BCMA-targeting), and leukemia (CD38-targeting)—demonstrating the platform's modularity. In Vivo Self-Assembly: A pilot study in a human lymphoma mouse model confirmed successful self-assembly in vivo after a two-step IV injection with a time lag (4-5 half-lives). A single treatment led to a complete response in mice after 75 days. Optimal Dosing Ratio: In a survival study, a 10-fold reduced dose of the T cell engager proved to be optimal for long-term survival (over 150 days) compared to the standard 1:1 ratio, validating the ability to enhance efficacy while decreasing the necessary T cell activation dose.

The Next Frontier: AI-Predicted Patient Dosing The team is currently developing a proprietary computational model to achieve truly patient-specific, stoichiometric dosing. Model Inputs: Patient data, including tumor burden, T cell counts, and cancer cell antigen profile, are fed into the model. Output: The model predicts the best custom multi-specific dose for that patient. Validation: An in vivo model of late-stage lymphoma showed that the AI-predicted MATCH formulation completely ablated the cancer cells with a single dose, outperforming an FDA-approved biosimilar. Partnership Opportunities: Thera-T Pharmaceutics is actively seeking pharma partners to help develop and advance the MATCH technology through IND submission for leukemia, lymphoma, and multiple myeloma.

Connect with Dr. Gambles: Contact information is provided at the end of the video.

This is your essential new resource for deep, technical insights in life sciences, cutting straight to the data that matters.

Forget the fluff and marketing speak – we're all about science, by scientists, for scientists.

What is The Bench Brief? We bring you concise, 10-15 minute video presentations from leading researchers, principal investigators (PIs), and innovators across the globe. Each episode dives into critical topics in immuno-oncology, antibody development, cell therapy, drug discovery, and advanced biological research.

Our content is designed for PhD-level expertise and above, ensuring you get high-impact, actionable scientific information.

💡 Want to Present Your Science on The Bench Brief? Are you a scientist with compelling data, a novel application, or a methodological advancement that deserves to be shared with a global audience of peers and industry leaders? We invite you to be a presenter!

Why Participate?

• Targeted Exposure: Showcase your work to researchers, potential collaborators, investors, and talent.
• Low Effort: Deliver a 10-15 minute presentation over 8-12 slides.
• We handle all the professional video production and distribution.
• Impact: Drive collaborations, recruitment, investment, or highlight your latest technology.

  🔗 Learn more about presenting & submit your topic here: https://ichor.bio/thebenchbrief